| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 31 | 2023 | 256 | 6.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 38 | 2023 | 1355 | 3.390 |
Why?
|
| Antineoplastic Agents | 34 | 2023 | 1879 | 3.300 |
Why?
|
| Neoplasms | 40 | 2023 | 2097 | 3.280 |
Why?
|
| Antibodies, Bispecific | 9 | 2023 | 32 | 2.350 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2023 | 64 | 1.540 |
Why?
|
| Medical Oncology | 5 | 2023 | 229 | 1.520 |
Why?
|
| Maximum Tolerated Dose | 21 | 2023 | 183 | 1.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 520 | 1.340 |
Why?
|
| Child | 66 | 2023 | 18412 | 1.190 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2022 | 858 | 1.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 71 | 1.120 |
Why?
|
| Antibodies, Monoclonal | 11 | 2018 | 1262 | 1.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 16 | 1.110 |
Why?
|
| Lymphoma, B-Cell | 6 | 2023 | 86 | 1.080 |
Why?
|
| Immunotherapy | 6 | 2023 | 474 | 1.050 |
Why?
|
| Pyridines | 6 | 2021 | 425 | 1.040 |
Why?
|
| Recurrence | 19 | 2023 | 935 | 0.980 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2022 | 534 | 0.920 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 56 | 0.900 |
Why?
|
| Leukemia | 6 | 2021 | 209 | 0.830 |
Why?
|
| Benzamides | 4 | 2021 | 169 | 0.820 |
Why?
|
| Etoposide | 7 | 2022 | 148 | 0.820 |
Why?
|
| Child, Preschool | 37 | 2023 | 9114 | 0.820 |
Why?
|
| Humans | 122 | 2023 | 114674 | 0.800 |
Why?
|
| Clinical Trials as Topic | 7 | 2022 | 932 | 0.740 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2018 | 16 | 0.710 |
Why?
|
| Adolescent | 41 | 2023 | 17841 | 0.710 |
Why?
|
| Treatment Outcome | 31 | 2023 | 9088 | 0.700 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2019 | 1842 | 0.690 |
Why?
|
| para-Aminobenzoates | 1 | 2019 | 5 | 0.680 |
Why?
|
| Deoxycytidine | 4 | 2011 | 138 | 0.680 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2018 | 95 | 0.680 |
Why?
|
| Hodgkin Disease | 2 | 2018 | 121 | 0.670 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 152 | 0.660 |
Why?
|
| Pyrrolidines | 1 | 2019 | 55 | 0.660 |
Why?
|
| Quinazolines | 3 | 2010 | 240 | 0.660 |
Why?
|
| Prodrugs | 1 | 2019 | 42 | 0.660 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 56 | 0.660 |
Why?
|
| Rare Diseases | 2 | 2017 | 89 | 0.650 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2021 | 198 | 0.650 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2022 | 785 | 0.650 |
Why?
|
| Brain Stem Neoplasms | 3 | 2017 | 86 | 0.640 |
Why?
|
| Dasatinib | 2 | 2018 | 46 | 0.620 |
Why?
|
| Azacitidine | 3 | 2020 | 129 | 0.610 |
Why?
|
| Astrocytoma | 3 | 2017 | 108 | 0.600 |
Why?
|
| Piperidines | 2 | 2010 | 160 | 0.590 |
Why?
|
| Female | 70 | 2022 | 59499 | 0.590 |
Why?
|
| Male | 70 | 2022 | 55589 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 663 | 0.580 |
Why?
|
| Immunoconjugates | 1 | 2018 | 87 | 0.570 |
Why?
|
| Glioma | 5 | 2022 | 294 | 0.570 |
Why?
|
| Poverty | 1 | 2021 | 442 | 0.570 |
Why?
|
| Biomedical Research | 3 | 2017 | 585 | 0.530 |
Why?
|
| Antigens, CD19 | 5 | 2023 | 91 | 0.520 |
Why?
|
| Administration, Oral | 9 | 2019 | 728 | 0.520 |
Why?
|
| Sirolimus | 2 | 2016 | 181 | 0.510 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 188 | 0.510 |
Why?
|
| Young Adult | 31 | 2023 | 10466 | 0.510 |
Why?
|
| Infant | 23 | 2023 | 7961 | 0.510 |
Why?
|
| Adult | 48 | 2023 | 30546 | 0.510 |
Why?
|
| Sulfonamides | 5 | 2020 | 445 | 0.510 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2023 | 184 | 0.500 |
Why?
|
| DNA Methylation | 2 | 2017 | 495 | 0.480 |
Why?
|
| Lymphoma | 2 | 2023 | 177 | 0.480 |
Why?
|
| Camptothecin | 3 | 2017 | 96 | 0.470 |
Why?
|
| Nausea | 3 | 2009 | 101 | 0.460 |
Why?
|
| Drug Administration Schedule | 10 | 2017 | 718 | 0.430 |
Why?
|
| Fluorouracil | 4 | 2012 | 152 | 0.430 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 4411 | 0.420 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.420 |
Why?
|
| DNA Damage | 5 | 2023 | 351 | 0.420 |
Why?
|
| Arsenicals | 1 | 2013 | 24 | 0.420 |
Why?
|
| Oxides | 1 | 2013 | 43 | 0.420 |
Why?
|
| Molecular Targeted Therapy | 5 | 2021 | 347 | 0.410 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2022 | 62 | 0.410 |
Why?
|
| Prognosis | 13 | 2021 | 3329 | 0.410 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 2010 | 5 | 0.390 |
Why?
|
| Neuroblastoma | 2 | 2023 | 133 | 0.380 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1040 | 0.380 |
Why?
|
| Vomiting | 2 | 2009 | 123 | 0.370 |
Why?
|
| Aged | 27 | 2022 | 19073 | 0.370 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2010 | 23 | 0.360 |
Why?
|
| Disease-Free Survival | 7 | 2023 | 620 | 0.350 |
Why?
|
| Infusions, Intravenous | 4 | 2019 | 371 | 0.340 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 217 | 0.330 |
Why?
|
| Pediatrics | 3 | 2008 | 979 | 0.330 |
Why?
|
| Middle Aged | 28 | 2022 | 26735 | 0.330 |
Why?
|
| Doxorubicin | 4 | 2021 | 285 | 0.330 |
Why?
|
| Everolimus | 2 | 2020 | 61 | 0.330 |
Why?
|
| Leukemia, B-Cell | 2 | 2021 | 11 | 0.320 |
Why?
|
| Carboplatin | 2 | 2009 | 135 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 636 | 0.320 |
Why?
|
| Arabinonucleosides | 2 | 2022 | 8 | 0.310 |
Why?
|
| Boronic Acids | 1 | 2008 | 33 | 0.300 |
Why?
|
| Morpholines | 1 | 2009 | 102 | 0.300 |
Why?
|
| Purine Nucleosides | 1 | 2007 | 3 | 0.300 |
Why?
|
| Farnesyltranstransferase | 1 | 2007 | 21 | 0.300 |
Why?
|
| Burkitt Lymphoma | 2 | 2023 | 52 | 0.300 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2007 | 12 | 0.300 |
Why?
|
| Pyrazines | 1 | 2008 | 71 | 0.300 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2020 | 119 | 0.280 |
Why?
|
| Pyrimidinones | 1 | 2007 | 88 | 0.280 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 1121 | 0.280 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 45 | 0.270 |
Why?
|
| Cisplatin | 1 | 2007 | 262 | 0.270 |
Why?
|
| Ethics, Medical | 1 | 2006 | 70 | 0.260 |
Why?
|
| Vincristine | 3 | 2021 | 98 | 0.260 |
Why?
|
| Glycine | 2 | 2019 | 152 | 0.260 |
Why?
|
| Cytarabine | 4 | 2020 | 51 | 0.260 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 561 | 0.260 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2014 | 214 | 0.260 |
Why?
|
| Craniopharyngioma | 2 | 2017 | 65 | 0.250 |
Why?
|
| Survival Rate | 6 | 2020 | 1644 | 0.250 |
Why?
|
| Pyrazoles | 1 | 2008 | 362 | 0.250 |
Why?
|
| Methotrexate | 2 | 2020 | 226 | 0.240 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 104 | 0.240 |
Why?
|
| Neuropilin-1 | 2 | 2014 | 9 | 0.230 |
Why?
|
| Prospective Studies | 9 | 2023 | 6219 | 0.220 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 6347 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2003 | 28 | 0.210 |
Why?
|
| Drug Delivery Systems | 3 | 2015 | 296 | 0.210 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2021 | 43 | 0.210 |
Why?
|
| Drug Discovery | 2 | 2015 | 123 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2021 | 96 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2020 | 358 | 0.210 |
Why?
|
| Plant Nectar | 1 | 2022 | 2 | 0.210 |
Why?
|
| Drug Design | 2 | 2017 | 148 | 0.210 |
Why?
|
| Nucleosides | 1 | 2022 | 25 | 0.200 |
Why?
|
| Osteosarcoma | 1 | 2003 | 67 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 811 | 0.200 |
Why?
|
| Cystectomy | 1 | 2022 | 32 | 0.200 |
Why?
|
| Neutropenia | 4 | 2017 | 125 | 0.200 |
Why?
|
| Capecitabine | 3 | 2011 | 45 | 0.190 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 15 | 0.190 |
Why?
|
| Glycolipids | 1 | 2021 | 35 | 0.190 |
Why?
|
| Vaping | 1 | 2022 | 45 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 168 | 0.190 |
Why?
|
| Tobacco Products | 1 | 2022 | 98 | 0.190 |
Why?
|
| Artificial Gene Fusion | 1 | 2000 | 4 | 0.180 |
Why?
|
| Area Under Curve | 4 | 2009 | 274 | 0.180 |
Why?
|
| Hematology | 1 | 2001 | 13 | 0.180 |
Why?
|
| Proto-Oncogenes | 1 | 2000 | 26 | 0.180 |
Why?
|
| Bone Marrow | 2 | 2019 | 243 | 0.180 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 71 | 0.180 |
Why?
|
| Weight Reduction Programs | 1 | 2022 | 94 | 0.180 |
Why?
|
| Carbazoles | 1 | 2021 | 78 | 0.180 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 2 | 0.180 |
Why?
|
| Acute Disease | 4 | 2023 | 911 | 0.180 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2021 | 47 | 0.180 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2020 | 172 | 0.170 |
Why?
|
| Mindfulness | 1 | 2022 | 98 | 0.170 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 1314 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 196 | 0.170 |
Why?
|
| Cohort Studies | 9 | 2022 | 4895 | 0.170 |
Why?
|
| United States | 9 | 2023 | 12182 | 0.170 |
Why?
|
| Cell Lineage | 1 | 2021 | 309 | 0.170 |
Why?
|
| Cytokines | 3 | 2017 | 1841 | 0.170 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Survivors | 1 | 2022 | 411 | 0.170 |
Why?
|
| Transcription Factors | 3 | 2002 | 1528 | 0.160 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 38 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 56 | 0.160 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 40 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2018 | 18 | 0.160 |
Why?
|
| Fetal Blood | 1 | 2000 | 270 | 0.160 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 377 | 0.150 |
Why?
|
| Melanoma | 3 | 2017 | 620 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 61 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 327 | 0.150 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 63 | 0.150 |
Why?
|
| Single-Blind Method | 2 | 2016 | 258 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2001 | 227 | 0.150 |
Why?
|
| Daunorubicin | 1 | 2017 | 24 | 0.150 |
Why?
|
| T-Lymphocytes | 3 | 2023 | 1737 | 0.150 |
Why?
|
| Ipilimumab | 1 | 2017 | 27 | 0.150 |
Why?
|
| United States Food and Drug Administration | 3 | 2023 | 172 | 0.150 |
Why?
|
| Cyst Fluid | 1 | 2017 | 27 | 0.150 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 17 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 979 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2021 | 205 | 0.140 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2017 | 31 | 0.140 |
Why?
|
| Dexamethasone | 3 | 2020 | 317 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2000 | 215 | 0.140 |
Why?
|
| Weight Loss | 1 | 2022 | 642 | 0.140 |
Why?
|
| Valine | 1 | 2017 | 72 | 0.140 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2010 | 91 | 0.140 |
Why?
|
| Age Factors | 4 | 2018 | 2894 | 0.140 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 18 | 0.140 |
Why?
|
| Oligopeptides | 1 | 2018 | 236 | 0.140 |
Why?
|
| Neoplasm Proteins | 3 | 2009 | 385 | 0.140 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 149 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 72 | 0.140 |
Why?
|
| Carbolines | 1 | 2017 | 27 | 0.140 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 16 | 0.140 |
Why?
|
| Pancreatitis | 1 | 2017 | 107 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 233 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2009 | 126 | 0.130 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 157 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 445 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2017 | 218 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 608 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2010 | 498 | 0.130 |
Why?
|
| RNA, Messenger | 5 | 2017 | 2553 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 520 | 0.130 |
Why?
|
| EGF Family of Proteins | 1 | 2015 | 15 | 0.120 |
Why?
|
| Paclitaxel | 2 | 2014 | 190 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 41 | 0.120 |
Why?
|
| Disease Progression | 4 | 2021 | 2380 | 0.120 |
Why?
|
| Bortezomib | 2 | 2020 | 41 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 763 | 0.120 |
Why?
|
| Remission Induction | 3 | 2022 | 233 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2015 | 88 | 0.120 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2014 | 4 | 0.120 |
Why?
|
| Sarcoma, Myeloid | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cetuximab | 2 | 2017 | 90 | 0.120 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 58 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 1167 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 61 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2014 | 316 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 61 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 328 | 0.110 |
Why?
|
| ErbB Receptors | 2 | 2015 | 554 | 0.110 |
Why?
|
| Apoptosis | 4 | 2010 | 2363 | 0.110 |
Why?
|
| Tissue Distribution | 2 | 2013 | 286 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 1211 | 0.110 |
Why?
|
| Sulfones | 1 | 2014 | 97 | 0.110 |
Why?
|
| Diphenylamine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 1131 | 0.110 |
Why?
|
| Immune System Diseases | 1 | 2013 | 32 | 0.110 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 28 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 239 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 395 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2022 | 1373 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2012 | 18 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 154 | 0.100 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 750 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 242 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 164 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 164 | 0.100 |
Why?
|
| Fatigue | 3 | 2009 | 294 | 0.100 |
Why?
|
| Dioxoles | 1 | 2011 | 9 | 0.100 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 1518 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 638 | 0.090 |
Why?
|
| HL-60 Cells | 1 | 2010 | 28 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 329 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 74 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 849 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 45 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 40 | 0.090 |
Why?
|
| Graft vs Host Disease | 2 | 2010 | 212 | 0.090 |
Why?
|
| Anemia | 2 | 2009 | 143 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 756 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 81 | 0.090 |
Why?
|
| Estrenes | 1 | 2010 | 15 | 0.090 |
Why?
|
| Glucuronidase | 2 | 2008 | 42 | 0.090 |
Why?
|
| Oligosaccharides | 2 | 2008 | 46 | 0.090 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 32 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2021 | 127 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2011 | 137 | 0.080 |
Why?
|
| Mice | 7 | 2023 | 14869 | 0.080 |
Why?
|
| Quality of Life | 2 | 2015 | 2353 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 86 | 0.080 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2021 | 14 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 88 | 0.080 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 26 | 0.080 |
Why?
|
| Hydrocortisone | 2 | 2022 | 267 | 0.080 |
Why?
|
| Animals | 9 | 2023 | 31705 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2008 | 351 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 98 | 0.080 |
Why?
|
| Ondansetron | 1 | 2009 | 8 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 31 | 0.080 |
Why?
|
| Celecoxib | 1 | 2008 | 38 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 102 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2022 | 740 | 0.080 |
Why?
|
| Hepatoblastoma | 1 | 2009 | 27 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 197 | 0.080 |
Why?
|
| Sulindac | 1 | 2008 | 17 | 0.080 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 18 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 98 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2010 | 2187 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 229 | 0.080 |
Why?
|
| Plateletpheresis | 1 | 2008 | 25 | 0.080 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2008 | 27 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 281 | 0.070 |
Why?
|
| Rhabdoid Tumor | 1 | 2009 | 80 | 0.070 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2008 | 66 | 0.070 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2007 | 21 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2010 | 542 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 103 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 698 | 0.070 |
Why?
|
| Models, Biological | 2 | 2018 | 1620 | 0.070 |
Why?
|
| Cell Survival | 1 | 2010 | 1021 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 14 | 0.070 |
Why?
|
| Research Design | 2 | 2018 | 928 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2007 | 22 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2008 | 138 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 68 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 276 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2007 | 99 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 12549 | 0.070 |
Why?
|
| Risk Factors | 2 | 2018 | 8632 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2007 | 46 | 0.070 |
Why?
|
| Fasting | 1 | 2008 | 240 | 0.070 |
Why?
|
| Estradiol | 1 | 2010 | 455 | 0.070 |
Why?
|
| Food | 1 | 2008 | 160 | 0.070 |
Why?
|
| Benzoquinones | 1 | 2007 | 44 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1214 | 0.070 |
Why?
|
| Flow Cytometry | 5 | 2014 | 1083 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 177 | 0.070 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 4 | 0.070 |
Why?
|
| Retreatment | 2 | 2016 | 67 | 0.070 |
Why?
|
| Microarray Analysis | 2 | 2017 | 118 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 238 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 21 | 0.070 |
Why?
|
| Risk | 1 | 2008 | 812 | 0.060 |
Why?
|
| Genotype | 3 | 2016 | 1760 | 0.060 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2017 | 34 | 0.060 |
Why?
|
| Time Factors | 4 | 2019 | 6115 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 282 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2005 | 116 | 0.060 |
Why?
|
| Blood Preservation | 1 | 2008 | 263 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1660 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2014 | 551 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2007 | 253 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 226 | 0.060 |
Why?
|
| DNA Primers | 2 | 2006 | 510 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2005 | 316 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2003 | 29 | 0.050 |
Why?
|
| Survival | 1 | 2003 | 37 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 41 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 56 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2003 | 68 | 0.050 |
Why?
|
| Biometry | 1 | 2022 | 62 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 68 | 0.050 |
Why?
|
| Morbidity | 1 | 2003 | 280 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 38 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2016 | 109 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 57 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 59 | 0.050 |
Why?
|
| Gangliosides | 1 | 2021 | 18 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2002 | 213 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2177 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 235 | 0.050 |
Why?
|
| Base Sequence | 2 | 2006 | 2114 | 0.050 |
Why?
|
| Smokers | 1 | 2022 | 129 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2002 | 171 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 9 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2022 | 278 | 0.050 |
Why?
|
| Furans | 1 | 2021 | 22 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2022 | 150 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2014 | 115 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 186 | 0.050 |
Why?
|
| Puerto Rico | 1 | 2001 | 51 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 3408 | 0.050 |
Why?
|
| Mutation | 3 | 2019 | 3346 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1421 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 101 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2020 | 12 | 0.040 |
Why?
|
| Certification | 1 | 2001 | 89 | 0.040 |
Why?
|
| Antigens | 1 | 2001 | 318 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3003 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2022 | 226 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 254 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2021 | 162 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 38 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2018 | 15 | 0.040 |
Why?
|
| Microsomes, Liver | 1 | 2018 | 55 | 0.040 |
Why?
|
| Midazolam | 1 | 2018 | 43 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 615 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 149 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 83 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2018 | 195 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1578 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2006 | 2968 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 338 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 112 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 2 | 2008 | 51 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1019 | 0.040 |
Why?
|
| Benzylamines | 1 | 2017 | 39 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2017 | 60 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 2313 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2001 | 368 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2017 | 78 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 243 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2022 | 772 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 11 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2001 | 822 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 537 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2016 | 32 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 740 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2016 | 60 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 88 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 150 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 82 | 0.030 |
Why?
|
| Caregivers | 1 | 2022 | 717 | 0.030 |
Why?
|
| Amphiregulin | 1 | 2015 | 21 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3046 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2018 | 3886 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 184 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2710 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 5045 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2285 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 641 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 110 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1629 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2014 | 161 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2008 | 1569 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2009 | 1701 | 0.030 |
Why?
|
| Phenotype | 1 | 2000 | 2796 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 37 | 0.030 |
Why?
|
| Leucovorin | 1 | 2012 | 43 | 0.030 |
Why?
|
| Syndrome | 1 | 2013 | 333 | 0.030 |
Why?
|
| Safety | 1 | 2014 | 297 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1141 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 808 | 0.020 |
Why?
|
| Research | 1 | 2015 | 394 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 4694 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2014 | 376 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1313 | 0.020 |
Why?
|
| Phosphotransferases | 1 | 2010 | 25 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 21 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2539 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2009 | 12 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
|
| Papilloma | 1 | 2009 | 43 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 80 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 66 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2508 | 0.020 |
Why?
|
| Alopecia | 1 | 2009 | 28 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 40 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 151 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 28 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2009 | 31 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 260 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 334 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 542 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2013 | 335 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 60 | 0.020 |
Why?
|
| Maximum Allowable Concentration | 1 | 2008 | 14 | 0.020 |
Why?
|
| Platelet Factor 4 | 1 | 2008 | 21 | 0.020 |
Why?
|
| DNA Repair | 1 | 2009 | 184 | 0.020 |
Why?
|
| Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2008 | 82 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 24 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 77 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 159 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 103 | 0.020 |
Why?
|
| Taxoids | 1 | 2008 | 93 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2014 | 4512 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 157 | 0.020 |
Why?
|
| ras Proteins | 1 | 2008 | 138 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 228 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 149 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 372 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 347 | 0.020 |
Why?
|
| Thymidine | 1 | 2006 | 58 | 0.020 |
Why?
|
| Heparin | 1 | 2008 | 224 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2006 | 26 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 157 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 470 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 25 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 171 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2008 | 192 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2008 | 273 | 0.020 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2006 | 43 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 182 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 331 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 180 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 411 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 448 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 304 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 493 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2006 | 162 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2006 | 266 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 504 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 923 | 0.010 |
Why?
|
| Yolk Sac | 1 | 2002 | 5 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 2002 | 33 | 0.010 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2002 | 31 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1692 | 0.010 |
Why?
|
| E2F2 Transcription Factor | 1 | 2001 | 15 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1430 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2001 | 55 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2001 | 52 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 72 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 4958 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2001 | 57 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1949 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 330 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 615 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 758 | 0.010 |
Why?
|
| Spleen | 1 | 2001 | 487 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 343 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 419 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 1147 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2002 | 800 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 2570 | 0.010 |
Why?
|